Fluorodeoxyglucose F18

• 

  Subject Areas on Research

  • (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 
  • (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes. 
  • (18)F-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis. 
  • (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 
  • 18-Fluorodeoxyglucose positron emission tomography in children and adolescents with traumatic brain injury. 
  • 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. 
  • 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. 
  • 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. 
  • 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. 
  • 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. 
  • 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. 
  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A systematic review of the factors affecting accuracy of SUV measurements. 
  • ACR Appropriateness Criteria® Suspected Pulmonary Hypertension. 
  • AJR teaching file: incidental breast cancer detected with 18F-FDG PET/CT. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. 
  • Accuracy of surface fit registration for PET and MR brain images using full and incomplete brain surfaces. 
  • Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. 
  • Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. 
  • Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. 
  • Alzheimer disease: operating characteristics of PET--a meta-analysis. 
  • Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography. 
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 
  • Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study. 
  • Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. 
  • Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. 
  • Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis. 
  • Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. 
  • Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. 
  • Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. 
  • Association of heat production with 18F-FDG accumulation in murine brown adipose tissue after stress. 
  • Attenuation correction in hybrid positron emission tomography. 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Brain FDG PET and the diagnosis of dementia. 
  • Cardiovascular Imaging With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients With Fibroinflammatory Disorders. 
  • Case 260: Endobronchial Posttransplantation Lymphoproliferative Disease. 
  • Cerebral imaging of decompression injury patients with 18-F-2-fluoro-2-deoxyglucose positron emission tomography. 
  • Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. 
  • Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer's disease. 
  • Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients. 
  • Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. 
  • Clinical and Technical Considerations for Brain PET Imaging for Dementia. 
  • Clinical oncologic positron emission tomography: an introduction. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. 
  • Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. 
  • Colonic schwannoma visualized on FDG PET/CT. 
  • Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. 
  • Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. 
  • Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging. 
  • Comparative effectiveness: 18F-FDG-PET/CT versus CT for post-treatment follow-up of patients with lung cancer. 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. 
  • Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. 
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. 
  • Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. 
  • Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. 
  • Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 
  • Diagnosing pulmonic valve infective endocarditis with positron emission tomography-CT. 
  • Diagnosis of pancreatic carcinoma: role of FDG PET. 
  • Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. 
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
  • Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. 
  • Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. 
  • Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. 
  • Early recognition of Alzheimer's disease: what is consensual? What is controversial? What is practical? 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 
  • Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. 
  • Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET. 
  • Evaluation of primary pulmonary carcinoid tumors using FDG PET. 
  • Evolving role of FDG PET/CT in multiple myeloma imaging and management. 
  • F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck. 
  • F-18 FDG PET/CT imaging of a parapharyngeal hemangioma. 
  • F-18 FDG PET/CT imaging of endogenous Cushing syndrome. 
  • F-18 FDG PET/CT imaging of intraventricular germinoma. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • F-18-FDG-PET/CT imaging of small cell carcinoma of the colon. 
  • FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. 
  • FDG PET imaging in patients with pathologically verified dementia. 
  • FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. 
  • FDG PET of pleural effusions in patients with non-small cell lung cancer. 
  • FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. 
  • FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. 
  • FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 
  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. 
  • FDG PET/CT in patients with HIV. 
  • FDG PET/CT in the management of colorectal and anal cancers. 
  • FDG PET/CT in the management of nasopharyngeal carcinoma. 
  • FDG PET/CT in the management of primary pleural tumors and pleural metastases. 
  • FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. 
  • FDG PET/CT of carcinoma showing thymus-like differentiation. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. 
  • FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. 
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. 
  • FDG-PET finding in early-phase Takayasu arteritis. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. 
  • FDG-PET imaging in patients with pulmonary carcinoid tumor. 
  • FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. 
  • FDG-PET in pediatric posterior fossa brain tumors. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. 
  • FDG-PET staging and importance of lymph node SUV in head and neck cancer. 
  • FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. 
  • FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. 
  • FDG-PET/CT characterization of adrenal nodules: diagnostic accuracy and interreader agreement using quantitative and qualitative methods. 
  • False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. 
  • Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. 
  • Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. 
  • Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Focal cerebral metabolic abnormality in a patient with continuous spike waves during slow-wave sleep. 
  • Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. 
  • Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management. 
  • Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. 
  • Fortuitous detection of papillary carcinoma of the thyroid with F-18 FDG positron emission tomography in a patient with non-Hodgkin lymphoma. 
  • Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. 
  • Gangliogliomas: characterization by registered positron emission tomography-MR images. 
  • Gated 99mTc-tetrofosmin and 18F-FDG studies: a comparison of single-acquisition and separate-acquisition protocols. 
  • Giant cell arteritis mimicking infiltrative leptomeningeal disease of the optic nerves. 
  • Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. 
  • Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. 
  • Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. 
  • Hibernoma: 18F FDG PET/CT imaging. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Human herpesvirus 6 limbic encephalitis after stem cell transplantation. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. 
  • Imaging biomarker roadmap for cancer studies. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions. 
  • Impact of PET staging in limited-stage small-cell lung cancer. 
  • Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors. 
  • Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. 
  • In vivo noninvasive detection of Brown Adipose Tissue through intermolecular zero-quantum MRI. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. 
  • Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. 
  • Influence of filter choice on 18F-FDG PET segmentation accuracy determined using generalized estimating equations. 
  • Interesting image. F-18 fluorodeoxyglocose positron emission tomography/computed tomography in the diagnosis of chronic myopathic sarcoidosis. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interpretation variability of 18FDG-positron emission tomography studies in dementia. 
  • Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. 
  • Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. 
  • Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 
  • Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. 
  • Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. 
  • Intrinsic radiomic expression patterns after 20 Gy demonstrate early metabolic response of oropharyngeal cancers. 
  • Is chronically dysfunctional yet viable myocardium distal to a severe coronary stenosis hypoperfused? 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery. 
  • Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. 
  • JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. 
  • Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. 
  • Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. 
  • Kaposi sarcoma after bilateral lung transplantation. 
  • Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography. 
  • Limbic encephalitis: comparison of FDG PET and MR imaging findings. 
  • Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment. 
  • Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. 
  • Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time. 
  • Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice. 
  • Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. 
  • Lung cancer and positron emission tomography with fluorodeoxyglucose. 
  • Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. 
  • Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. 
  • Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. 
  • Metastatic melanoma to the heart. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology. 
  • Molecular imaging in Alzheimer's disease. 
  • Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. 
  • Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images. 
  • Neuronal migration disorders: positron emission tomography correlations. 
  • Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Normal brain F-18 FDG-PET and MRI anatomy. 
  • Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. 
  • Oncologic 18F-FDG PET/CT: referring physicians' point of view. 
  • PET Imaging for Head and Neck Cancers. 
  • PET and brain tumor image fusion. 
  • PET appearance of tuberculous empyema necessitans. 
  • PET imaging in patients with bronchioloalveolar cell carcinoma. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors. 
  • PET/CT of Dementia. 
  • PET/CT of cancer patients: part 1, pancreatic neoplasms. 
  • PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 
  • PET/Computed Tomography and Precision Medicine: Gastric Cancer. 
  • PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma. 
  • Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. 
  • Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. 
  • Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation. 
  • Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. 
  • Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. 
  • Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. 
  • Positron emission tomography detection of metastatic penile squamous cell carcinoma. 
  • Positron emission tomography imaging in the thorax. 
  • Positron emission tomography imaging of brain tumors. 
  • Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Positron emission tomography scanning in malignant melanoma. 
  • Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. 
  • Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. 
  • Positron emission tomography: brain tumors and lung cancer. 
  • Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study. 
  • Precision Medicine and PET-Computed Tomography in Pediatric Malignancies. 
  • Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. 
  • Primary muscle lymphoma: clinical and imaging findings. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. 
  • Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. 
  • Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prospective investigation of positron emission tomography in lung nodules. 
  • Pulmonary abnormalities and PET data analysis: a retrospective study. 
  • Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms. 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. 
  • Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. 
  • Recent developments in predicting thyroid malignancy. 
  • Recommendations on the use of 18F-FDG PET in oncology. 
  • Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. 
  • Regional brain activity correlates of nicotine dependence. 
  • Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. 
  • Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. 
  • Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. 
  • Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. 
  • Role of Non-FDG-PET/CT in Head and Neck Cancer. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. 
  • Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. 
  • Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. 
  • Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. 
  • Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. 
  • T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. 
  • Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. 
  • Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy. 
  • Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. 
  • Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. 
  • The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. 
  • The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. 
  • The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. 
  • The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. 
  • The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. 
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. 
  • The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. 
  • The role of PET scanning in the detection of recurrent cervical cancer. 
  • The role of PET/CT in the management of cervical cancer. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. 
  • The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. 
  • The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. 
  • The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma. 
  • Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. 
  • Thoracic FDG PET: state of the art. 
  • Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. 
  • Transmission scanning system for a gamma camera coincidence scanner. 
  • Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. 
  • Two-time-point FDG PET/CT: liver SULmean repeatability. 
  • Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer. 
  • Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. 
  • Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Utility of FDG PET/CT in inflammatory cardiovascular disease. 
  • Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. 
  • Validation of consensus panel diagnosis in dementia. 
  • Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. 
  • Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. 
  • Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer. 
  • Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. 
  • Value of PET/CT in the management of liver metastases, part 1. 
  • Value of PET/CT in the management of primary hepatobiliary tumors, part 2. 
  • Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer. 
  • Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. 
  • Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. 
  • Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. 
  • [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. 
  • [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. 
  • ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology